Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer.
Roberti MP, Yonekura S, Duong CPM, Picard M, Ferrere G, Tidjani Alou M, Rauber C, Iebba V, Lehmann CHK, Amon L, Dudziak D, Derosa L, Routy B, Flament C, Richard C, Daillère R, Fluckiger A, Van Seuningen I, Chamaillard M, Vincent A, Kourula S, Opolon P, Ly P, Pizzato E, Becharef S, Paillet J, Klein C, Marliot F, Pietrantonio F, Benoist S, Scoazec JY, Dartigues P, Hollebecque A, Malka D, Pagès F, Galon J, Gomperts Boneca I, Lepage P, Ryffel B, Raoult D, Eggermont A, Vanden Berghe T, Ghiringhelli F, Vandenabeele P, Kroemer G, Zitvogel L. Roberti MP, et al. Among authors: pietrantonio f. Nat Med. 2020 Jun;26(6):919-931. doi: 10.1038/s41591-020-0882-8. Epub 2020 May 25. Nat Med. 2020. PMID: 32451498 Free article.
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, Pietrantonio F, Ferrere G, Fahrner JE, Le Chatellier E, Pons N, Galleron N, Roume H, Duong CPM, Mondragón L, Iribarren K, Bonvalet M, Terrisse S, Rauber C, Goubet AG, Daillère R, Lemaitre F, Reni A, Casu B, Alou MT, Alves Costa Silva C, Raoult D, Fizazi K, Escudier B, Kroemer G, Albiges L, Zitvogel L. Derosa L, et al. Among authors: pietrantonio f. Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4. Eur Urol. 2020. PMID: 32376136 Free article.
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment.
Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S, Zitvogel L. Terrisse S, et al. Among authors: pietrantonio f. Cell Death Differ. 2021 Sep;28(9):2778-2796. doi: 10.1038/s41418-021-00784-1. Epub 2021 May 7. Cell Death Differ. 2021. PMID: 33963313 Free PMC article.
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Sartore-Bianchi A, et al. Among authors: pietrantonio f. Nat Med. 2022 Aug;28(8):1612-1618. doi: 10.1038/s41591-022-01886-0. Epub 2022 Aug 1. Nat Med. 2022. PMID: 35915157 Free PMC article. Clinical Trial.
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, Ugolini C, Proietti A, Conca V, Kassambara A, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, Tamburini E, Poma AM, Fieschi J, Fontanini G, Masi G, Galon J, Cremolini C. Moretto R, et al. Among authors: pietrantonio f. J Immunother Cancer. 2023 Apr;11(4):e006633. doi: 10.1136/jitc-2022-006633. J Immunother Cancer. 2023. PMID: 37085190 Free PMC article.
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Germano G, et al. Among authors: pietrantonio f. Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29. Nature. 2017. PMID: 29186113 Free article.
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.
De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M. De Santis F, et al. Among authors: pietrantonio f. Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30. Cytokine Growth Factor Rev. 2018. PMID: 30393044
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.
Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. Elez E, et al. Among authors: pietrantonio f. Nat Med. 2022 Oct;28(10):2162-2170. doi: 10.1038/s41591-022-01976-z. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097219 Free PMC article.
Role of BAX for outcome prediction in gastrointestinal malignancies.
Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Pietrantonio F, et al. Med Oncol. 2013;30(3):610. doi: 10.1007/s12032-013-0610-z. Epub 2013 May 23. Med Oncol. 2013. PMID: 23700226 Review.
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F. Pietrantonio F, et al. J Transl Med. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x. J Transl Med. 2016. PMID: 27154293 Free PMC article. Clinical Trial.
371 results